Blueprint Medicines Corporation (NASDAQ:BPMC) is expected to reveal earnings on May, 1., according to Faxor. Analysts forecast $-1.79 EPS. That’s $0.50 down or 38.76 % from 2018’s earnings of $-1.29. After $-1.83 EPS was published previous quarter, analysts now see EPS growth of -2.19 % for Blueprint Medicines Corporation. Ticker’s shares touched $83.21 during the last trading session after 1.24% change.Blueprint Medicines Corporation has 522,179 shares volume, 14.36% up from normal. BPMC is downtrending and has moved 5.66% since April 8, 2018. BPMC underperformed by 10.03% the S&P 500.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases.The firm is worth $4.00 billion. The Company’s lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.Currently it has negative earnings. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase and predicted NTRK resistant mutants.

For more Blueprint Medicines Corporation (NASDAQ:BPMC) news brought out recently go to: Seekingalpha.com, Nasdaq.com, Nasdaq.com, or Nasdaq.com. The titles are as follows: “Blueprint Medicines: An Infrequent, Timely Buy – Seeking Alpha” brought out on November 11, 2018, “Are These The Next Biotech Buyout Targets? – Nasdaq” on January 22, 2019, “What’s Behind the Biotech ETF Rally to Start 2019? – Nasdaq” with a publish date: January 24, 2019, “The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Yahoo! Finance News” and the last “Why #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% Today – Nasdaq” with publication date: June 04, 2018.